Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152
View directory record Official record
Conditions
Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions
National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 23, 2026, 8:53 AM EDT
Active, not recruiting No phase listed Observational

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

NCT05319990
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions
Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

NCT00659789
View directory record Official record
Conditions
HIV I Infection
Interventions
Vacc-4x, Sterile water
Drug
Lead sponsor
Bionor Immuno AS
Industry
Eligibility
18 Years to 55 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 8:53 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

High-Resolution Measurements of Diet-Microbiome Interactions

NCT07856823
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome)
Interventions
Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule
Dietary Supplement · Other · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Energetics and Function in Older Humans

NCT02348762
View directory record Official record
Conditions
Aging, Erythrocyte Glutathione Deficiency, Muscle Weakness
Interventions
Cysteine (as n-acetylcysteine) and Glycine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Infant Feeding on Stool Characteristics

NCT00503789
View directory record Official record
Conditions
Healthy
Interventions
fecal bacteria analysis
Procedure
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
21 Days to 30 Days
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
23
States / cities
Benton, Arkansas • Conway, Arkansas • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2008 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Phase 2 Interventional

Motivation for IV Alcohol Self-Administration in Humans

NCT06494891
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

NCT05636618
View directory record Official record
Conditions
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Interventions
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Glycemic Control With Electrical Stimulation

NCT03947697
View directory record Official record
Conditions
Obesity, Overweight, Insulin Resistance
Interventions
Neuromuscular Electrical Stimulation (Sensory), Neuromuscular Electrical Stimulation, Resistance Training
Device · Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779
View directory record Official record
Conditions
Malaria
Interventions
Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 23, 2026, 8:53 AM EDT
Not listed Not applicable Interventional

In Vitro Maturation of Human Eggs

NCT02516462
View directory record Official record
Conditions
Infertility, Reproductive Techniques, Assisted
Interventions
IVM media, Follicle Stimulating Hormone (FSH)
Device · Drug
Lead sponsor
National Foundation for Fertility Research
Other
Eligibility
21 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional

The STOP-HPV Scale Up Study

NCT06831383
View directory record Official record
Conditions
Human Papilloma Virus Vaccine
Interventions
STOP-HPV-Online, STOP-HPV-LC
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 17 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

NCT00625729
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 8:53 AM EDT
Terminated Phase 1 Interventional

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT04956302
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Panobinostat Lactate
Drug
Lead sponsor
Abdullah Khan
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

NCT06803875
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
Interventions
Autologous hALK.CAR T cells
Biological
Lead sponsor
Roberto Chiarle
Other
Eligibility
12 Months to 29 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

NCT04660812
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy

NCT03083379
View directory record Official record
Conditions
Ventilation, Breathing, Atelectasis
Interventions
Volumetric Incentive Spirometry, EzPAP® POSITIVE AIRWAY PRESSURE
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 23, 2026, 8:53 AM EDT
Completed No phase listed Observational

Evaluation of Antibody Tests for COVID-19

NCT04360954
View directory record Official record
Conditions
COVID, Coronavirus
Interventions
Diagnostic test
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
461 participants
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

NCT03845231
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax(R), Human Challenge virus
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of Atropine and Propranolol Induced Changes

NCT00251602
View directory record Official record
Conditions
Healthy
Interventions
Atropine, Propranolol, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Oct 23, 2026, 8:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulating Deep Brain Regions With a Magnetic Stimulator

NCT00063245
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
Vofatamab, Docetaxel, Placebo
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 23, 2026, 8:53 AM EDT
Recruiting Phase 2 Interventional

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT05847569
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 8:53 AM EDT